Amyotrophic lateral sclerosis (ALS) Treatment Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025 the global amyotrophic lateral sclerosis treatment market was valued at US$ 51.04 Mn in 2016, and is expected to reach US$ 306.6 Mn by 2025, expanding at a CAGR of 21.1% from 2017 to 2025.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes death of nerve cells that control voluntary muscles. According to National Organization for Rare Disorders (NORD), ALS is a is a rare disorder that affects approximately 30,000 people in the United States, approximately 5,000 new cases are diagnosed each year in the United States. Currently, there is no cure for ALS however, treatments are available to control symptoms and to prevent complications. The U.S. Food and Drug Administration (FDA) has approved only two drugs for the treatment of ALS it includes Riluzole and Edaravone, other medications are prescribe to control ALS symptoms. It is studied that in the base year 2016, Riluzole (Rilutek) was major revenue generating segment because riluzole was the only approved drug for a treatment of ALS, however patent expiry of Rilutek in 2013 has been negatively impacting the ALS treatment market growth. On the other hand, recently approved medication Edaravone (Radicava) expected to show highest growth rate during forecast period due to its applicability and higher cost would drive market growth. Moreover strong pipeline molecule such as AB-1010 (masitinib), Methycobal (mecobalamin), Arimoclomol, CK-2017357 (CK-357, tirasemtiv) would assist ALS treatment market growth during forecast period. It is observed that, in the base year 2016, North America was dominating ALS treatment market in terms of revenue due to the factors such as upsurge in funding by government agencies and private organizations in healthcare system, increase in prevalence of the neurological diseases and higher treatment awareness are fueling market growth in North America. It is anticipated that, Asia Pacific will grow significantly during forecast period due to increasing healthcare awareness, increasing partnership of key players such as Biogen, Avicena, Mitsubishi Tanabe, and Sanofi with local manufacturer, populous countries and developing economic condition would fuel ALS treatment market growth.
Market Competition Assessment:
The Amyotrophic lateral sclerosis (ALS) market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as AB Science, Avicena Group, Biogen, BrainStorm Therapeutics, Covis Pharmaceutical Inc., Cytokinetics Inc., Eisai Co. Ltd., GlaxoSmithKline plc., Ionis Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corp., Neuralstem Inc., Neuraltus Pharmaceuticals Inc., Newron Pharmaceuticals S.p.A., Nutra Pharma Corp., Pharnext SAS, Q-Therapeutics Inc. and other.
Key Market Movements:
– Factors such as increasing treatment awareness, increase in incidence of ALS, strong pipeline molecules, rising geriatric population, favorable reimbursement policies in some countries and expected launch of newer medication would drive the growth of ALS treatment market globally.
– Due to the higher number of unmet needs, manufacturers in the market are focusing on innovation and technological advances in treatment options would further influence the growth of ALS treatment market globally.
Table of Content:
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
Chapter 2 Executive Summary
2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Snapshot
2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, Drug Type
2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share, by Geography, 2016 (Value %)
Chapter 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.3 Pipeline Analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment Market
3.4 Epidemiology of Amyotrophic lateral sclerosis (ALS)
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Chapter 6 Company Profiles
6.1 AB Science
6.2 Avicena Group
6.4 BrainStorm Therapeutics
6.5 Covis Pharmaceutical Inc.
6.6 Cytokinetics Inc.
6.7 Eisai Co. Ltd.
6.8 GlaxoSmithKline plc.
6.9 Ionis Pharmaceuticals, Inc.
6.10 Mitsubishi Tanabe Pharma Corp.
6.11 Neuralstem Inc.
6.12 Neuraltus Pharmaceuticals Inc.
6.13 Newron Pharmaceuticals S.p.A.
6.14 Nutra Pharma Corp.
6.15 Pharnext SAS
6.16 Q-Therapeutics Inc.
Download Free Request Sample: http://www.acutemarketreports.com/request-free-sample/109054
About – Acute Market Reports:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Company Name: Acute Market Reports
Contact Person: Chris Paul
Phone: India: +91 7755981103, Toll Free US/Canada: +1-855-455-8662
Address:Office No 01, 1st Floor, Aditi Mall, Baner